Robert B. Lally, Principal Accounting Officer at ImageneBio, Inc. (), sold a total of $17,334 worth of common stock in two transactions last week. The sales occurred at prices ranging from $5.34 to $5.5 per share.
On July 16, 2026, Mr. Lally disposed of 1,671 shares of ImageneBio common stock. These shares were sold at a weighted average price of $5.5 per share, with individual transaction prices ranging from $5.45 to $5.635.
The following day, July 17, 2026, an additional 1,525 shares were sold. These shares traded at a weighted average price of $5.34, with prices for individual transactions falling between $5.32 and $5.3527.
Following these transactions, Mr. Lally directly holds 55,582 shares of ImageneBio common stock.The insider sale comes as ImageneBio stock trades at $5.73, down 65% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company holding more cash than debt on its balance sheet. The biotech firm carries a market capitalization of $64.63 million but remains unprofitable with a WEAK financial health score. InvestingPro offers 5 additional exclusive tips for IMA investors.
In other recent news, ImageneBio, Inc. announced that its stockholders have approved an amendment to the company’s 2025 Equity Incentive Plan. This amendment was ratified at the company’s annual meeting and involves an increase of 850,000 shares of common stock authorized for issuance. The amended plan also includes shares issuable upon conversion or exercise of convertible preferred stock and prefunded warrants in the annual automatic share reserve increase calculation. The board of directors had previously given their approval for this amendment, pending stockholder consent. Details about the material terms of the amended plan are available in the company’s definitive proxy statement filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.